

Edgar Filing: VistaGen Therapeutics, Inc. - Form 8-K

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	VTGN	Nasdaq Capital Market

Item 7.01 Regulation FD Disclosure.

VistaGen Therapeutics, Inc. (the “Company”) today began utilizing a new corporate presentation. A copy of the Corporate Presentation is attached hereto as Exhibit 99.1.

The information in this Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01 Other Items.

The Company today announced topline results from an exploratory clinical study of AV-101 as a monotherapy in patients with treatment-resistant depression (“TRD”). The 19-patient study was sponsored and conducted by the U.S National Institute of Mental Health (“NIMH”). A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.2.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits Index

Exhibit No. Description

<u>99.1</u>	Corporate Presentation, dated May 2, 2019
<u>99.2</u>	Press Release issued by VistaGen Therapeutics, Inc., dated May 2, 2019.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

VistaGen Therapeutics,
Inc.

Date: May 2, 2019 By: /s/ Shawn K.
 Singh
 Shawn K. Singh
 Chief Executive
 Officer

EXHIBIT INDEX

Exhibit No. Description

99.1 Corporate Presentation, dated May 2, 2019

99.2 Press Release issued by VistaGen Therapeutics, Inc., dated May 2, 2019.